Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.80.

A number of research firms have recently commented on IMTX. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research report on Tuesday, May 19th. TD Cowen assumed coverage on Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd.

Immatics Price Performance

Shares of Immatics stock opened at $9.08 on Monday. The firm has a fifty day moving average price of $9.97 and a 200 day moving average price of $10.11. Immatics has a 1 year low of $5.05 and a 1 year high of $12.41. The stock has a market cap of $1.22 billion, a PE ratio of -4.56 and a beta of 1.32.

Immatics (NASDAQ:IMTX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The company had revenue of $8.81 million for the quarter, compared to analyst estimates of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. As a group, equities analysts expect that Immatics will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Immatics

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in Immatics during the fourth quarter worth $2,189,000. Sofinnova Investments Inc. grew its holdings in Immatics by 54.2% in the 4th quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock valued at $36,073,000 after buying an additional 1,207,705 shares in the last quarter. Monashee Investment Management LLC acquired a new stake in shares of Immatics in the 4th quarter worth $1,684,000. Ishara Investments LP acquired a new stake in shares of Immatics in the 4th quarter worth $840,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Immatics during the 1st quarter worth $742,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.